Aethlon Medical Inc (AEMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aethlon Medical Inc (AEMD) has a cash flow conversion efficiency ratio of -364.766x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.90 Billion) by net assets ($5.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Aethlon Medical Inc market cap and net worth for the company's overall valuation and market capitalisation.
Aethlon Medical Inc - Cash Flow Conversion Efficiency Trend (1997–2026)
This chart illustrates how Aethlon Medical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aethlon Medical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aethlon Medical Inc ranked by their cash flow conversion efficiency. Explore Aethlon Medical Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
River and Mercantile UK Micro Cap Investment Company Ltd
LSE:RMMC
|
-0.007x |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
N/A |
|
Edri-El
TA:EDRL
|
0.013x |
|
Value & Income Trust
LSE:VIP
|
0.013x |
|
General Shopping e Outlets do Brasil S.A.
SA:GSHP3
|
0.003x |
|
Wynnstay Group Plc
LSE:WYN
|
-0.056x |
|
PHAXIAM Therapeutics S.A.
PA:PHXM
|
-0.540x |
|
BioNeutra Global Corp
V:BGA
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Aethlon Medical Inc (1997–2026)
The table below shows the annual cash flow conversion efficiency of Aethlon Medical Inc from 1997 to 2026. View Aethlon Medical Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $4.89 Million | $-7.00 Million | -1.432x | +4.02% |
| 2025-03-31 | $5.12 Million | $-7.65 Million | -1.492x | +15.06% |
| 2024-03-31 | $5.77 Million | $-10.13 Million | -1.757x | -151.91% |
| 2023-03-31 | $15.06 Million | $-10.51 Million | -0.697x | -21.32% |
| 2022-03-31 | $16.99 Million | $-9.77 Million | -0.575x | +21.03% |
| 2021-03-31 | $9.29 Million | $-6.76 Million | -0.728x | -29.93% |
| 2020-03-31 | $9.28 Million | $-5.20 Million | -0.560x | +70.00% |
| 2019-03-31 | $2.30 Million | $-4.29 Million | -1.867x | -188.08% |
| 2018-03-31 | $6.03 Million | $-3.91 Million | -0.648x | +88.99% |
| 2017-03-31 | $595.41K | $-3.51 Million | -5.888x | -104.33% |
| 2016-03-31 | $1.50 Million | $-4.33 Million | -2.882x | +62.83% |
| 2015-03-31 | $651.38K | $-5.05 Million | -7.752x | -5438.35% |
| 2014-03-31 | $-14.73 Million | $-2.14 Million | 0.145x | -36.73% |
| 2013-03-31 | $-9.14 Million | $-2.10 Million | 0.230x | +15.87% |
| 2012-03-31 | $-9.30 Million | $-1.84 Million | 0.198x | -39.86% |
| 2011-03-31 | $-5.98 Million | $-1.97 Million | 0.329x | -26.67% |
| 2010-03-31 | $-4.40 Million | $-1.98 Million | 0.449x | -0.19% |
| 2009-03-31 | $-3.95 Million | $-1.78 Million | 0.450x | -28.95% |
| 2008-03-31 | $-3.32 Million | $-2.10 Million | 0.633x | +161.32% |
| 2007-03-31 | $-7.09 Million | $-1.72 Million | 0.242x | -73.08% |
| 2006-03-31 | $-1.76 Million | $-1.58 Million | 0.900x | +77.10% |
| 2005-03-31 | $-3.07 Million | $-1.56 Million | 0.508x | +242.85% |
| 2004-03-31 | $-3.66 Million | $-542.06K | 0.148x | +4.50% |
| 2003-03-31 | $-3.63 Million | $-514.50K | 0.142x | -69.05% |
| 2002-03-31 | $-2.20 Million | $-1.01 Million | 0.458x | +41.19% |
| 2001-03-31 | $-2.47 Million | $-800.67K | 0.325x | -65.90% |
| 2000-03-31 | $-713.05K | $-678.93K | 0.952x | +446.46% |
| 1999-03-31 | $-704.50K | $-122.75K | 0.174x | -88.46% |
| 1998-03-31 | $-1.23K | $-1.85K | 1.510x | +261.57% |
| 1997-03-31 | $2.37K | $-2.22K | -0.935x | -- |
About Aethlon Medical Inc
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.